Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 5 ... of more than 72% for arsenic(III)-oxide (As(2)O(3)) treatment in relapsed or refractory acute promyelocytic leukemia have been published. As(2)O(3) is under clinical investigation for therapy of leukemia ...
2009 SEP 28 ... (arsenic trioxide) injection (marketed by Cephalon, Inc.) in patients with relapsed acute promyelocytic leukemia (APL). There are two primary trial objectives. The first is to determine the safety and ...
2009 NOV 1 ... potentially important oncology drug candidates, such as tamibarotene as a treatment for acute promyelocytic leukemia (APL) and INNO-206, a drug that has shown statistically significant tumor shrinkage in ...
2009 NOV 23 ... step aimed at broadening the market opportunity for tamibarotene as a treatment for acute promyelocytic leukemia, or APL," he added. "In September, a dose escalating trial with tamibarotene in ...
2009 SEP 14 ... efficacy and safety of orally administered tamibarotene as a third-line treatment for acute promyelocytic leukemia (APL). The primary endpoint of the open-label, non-randomized STAR-1 trial ...
2009 NOV 1 ... prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established and remain a controversial matter. Between 1996 and 2005, 739 ...
2009 NOV 1 ... these compounds were evaluated with four cancer cell lines such as A-549 (lung), HL-60 (acute promyelocytic leukemia), MCF-7 (breast), and U-937 (leukemia)," wrote N.X. Nhiem and colleagues, Chungnam ...
2009 SEP 14 ... box 2 (ASB2) gene that we initially identified as a retinoic acid-response gene in acute promyelocytic leukemia cells encodes the specificity subunit of an E3 ubiquitin ligase complex that is involved ...
2009 SEP 14 ... from the United States, "Arsenic trioxide (As2O3) is a frontline drug for treatment of acute promyelocytic leukemia and is in clinical trials for treatment of other malignancies, including multiple ...
2009 NOV 2 ... Investigators publish new data in the report 'Acute promyelocytic leukemia in childhood.' According to recent research from the United States, ...
2009 SEP 28 ... to a study from Hongo, Japan, "Although European conventional maintenance therapy for acute promyelocytic leukemia consisting of all-trans retinoic acid, 6-mercaptopurine, and methotrexate has been ...
2009 OCT 5 ... "We analyzed the clinical impact of FLT3 alterations in adult AML patients excluding acute promyelocytic leukemia (APL) who received induction chemotherapy according to morphologic classification. ...
2009 SEP 7 ... in cell death. We show that dexamethasone induced autophagy upstream of apoptosis in acute lymphoblastic leukemia cells. Inhibition of autophagy by siRNA-mediated repression of ... in dexamethasone-induced cell death. Dexamethasone treatment caused an upregulation of promyelocytic leukemia protein, PML, its complex formation with protein kinase B or Akt and a ...
2009 NOV 9 ... cell mechanics, isolated from other parameters, in the context of tissue infiltration by acute promyelocytic leukemia (APL) cells, which occurs during differentiation therapy with retinoic acid. Compliance ...
2009 SEP 28 ... lymphoma as a secondary malignancy in a young patient after successful treatment of acute promyelocytic leukemia,' have been published. "Acute promyelocytic leukemia ...
2009 NOV 2 ... survival (DFS) is 28%. The most important prognostic factor was cytogenetics, with acute promyelocytic leukemia (APL) patients having a 5-year DFS of 67% compared with 16% for others," wrote C.A. ...
2009 NOV 2 ... white blood cell (WBC) count to assist with the selection of treatment for patients with acute promyelocytic leukemia (APL), a subtype of AML. New pages were added to the NCCN Guidelines to ...
